Novotech Launches Dedicated Early Phase Unit for Biotechs Leveraging the Australian and New Zealand
SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- Novotech, the global full-service Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, today announced the launch of a dedicated early phase unit focussed on leveraging the unique advantage of Australian and New Zealand (ANZ) for early phase clinical development.
This Early Phase Strategic Delivery Unit (EP SDU) is the first in a series of new Strategic Delivery Units (SDUs) to be launched by Novotech over the course of 2024, each one being a dedicated delivery unit with specialist teams and tailored processes, for different types of complex clinical trials.
Novotech has long been a partner of choice for biotechs wanting to conduct early phase trials in ANZ and benefit from the clinical and scientific excellence, attractive financial rebates, and rapid start-up with streamlined regulatory processes.
Novotech CEO Dr John Moller said: “Our Early Phase Strategic Delivery Unit ensures that, as our global operations continue to grow, our commitment to excellence in Phase I delivery across ANZ remains a core and integral part of Novotech's service offering. This continues to serve as a platform for our biotech clients to expedite their early phase work before expanding into later phase global development with Novotech.”
Lynda Bluck, Director of Early Phase Project Management, who brings over 20 years of clinical trial experience said: “The EP SDU consists of a multidisciplinary team of experts in early phase clinical trials who provide support, expertise, guidance, and oversight to all our early phase projects, ensuring consistent high quality operational delivery.”
“ANZ is an attractive destination for early phase biotechs as it offers rapid, cost-effective, and high-quality clinical development solutions,” said Bluck.
“Novotech has more than 30 years of experience in conducting early phase clinical trials in ANZ with a reputation for consistently delivering high quality data that is accepted by international regulatory agencies.”
“Our team offers proven optimized processes for rapid and efficient execution of Phase I clinical trials and are committed to helping our sponsors navigate both the preclinical and clinical stages of drug development.”
Bluck said central to the EP SDU’s offering is integrated engagement with Novotech's world-class Drug Development Consulting (DDC) team.
“The DDC is a full-service global product development and strategic regulatory group that supports sponsors through every phase of clinical development. The expert team is particularly integral in providing guidance and support prior to entering Phase I and ensuring our sponsors are HREC (IRB equivalent) ready,” said Scott Schliebner, Novotech’s Vice President of Drug Development Consulting.
Novotech's DDC team provides comprehensive "lab to launch" program development services, including regulatory strategy and operations, CMC and product/analytical consulting, clinical oversight, toxicology and other nonclinical consulting, quality/GMP consulting, and electronic submissions. We have a proven track record of successful FDA meetings and approvals.
The teams have the expertise to support projects over their entire lifecycle, all the way from preclinical development through to approval and post-marketing.
About Novotech Novotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com
Media Contact
David James
mediacontact@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427
